Quantcast

Latest Multiple Myeloma Research Foundation Stories

2009-02-06 11:11:00

LOS ANGELES, Feb. 6 /PRNewswire-USNewswire/ -- Established in 2004, the Institute for Myeloma and Bone Cancer Research (IMBCR) is the only non-profit, independent cancer research institute focused on creating novel therapies and ultimately a cure for multiple myeloma and metastatic bone disease. Ethan Horwitz, Esq. is a partner in New York law firm of King & Spalding and has an extensive Intellectual Property practice. Mr. Horwitz has over 25 years of experience in the full range of...

2009-01-26 10:00:00

FJC, a foundation of philanthropic donor-advised funds and the Myeloma Research Foundation are the latest major donors to the "Cure Myeloma Project", an ongoing research initiative at the Institute for Myeloma and Bone Cancer Research, (IMBCR), in Los Angeles, CA LOS ANGELES, Jan. 26 /PRNewswire-USNewswire/ -- IMBCR's "Cure Myeloma Project" is the nation's foremost effort to find a cure for multiple myeloma, a blood cancer that resides in bone marrow. Led by premier scientists in the world...

2008-11-06 15:00:28

The International Myeloma Foundation (IMF)--supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians--today called for all patients to have access to the newest pharmaceuticals making life-changing advances in the treatment of myeloma. REVLIMID(R), THALOMID(R) (global thalidomide) and VELCADE(R), known collectively as the "novel therapies," have extended survival and improved quality of life for patients with the blood...

2008-10-23 15:00:28

Certain genes can influence a person's likelihood to contract and recover from a particular disease such as cancer, U.S. researchers said. Brian Van Ness of the University of Minnesota identified combinations of genes associated with early clinical relapse of multiple myeloma, a cancer of the white blood cells that produce antibodies. The results raise the possibility a patient's genetic background exerts an important influence on the patient's prognosis and response to treatment, Van...

2008-10-17 09:00:27

Celgene and Acceleron Pharma have initiated a Phase II clinical study of its lead compound ACE-011 in patients with multiple myeloma. Celgene will make a $5 million milestone payment to Acceleron in accordance with the terms of the collaboration agreement between the two companies. The Phase II, multi-center, randomized, double-blind, placebo-controlled study is designed to assess the safety and efficacy of multiple doses of ACE-011 in multiple myeloma patients with osteolytic bone lesions....

2008-10-16 09:00:10

Celgene Corporation (NASDAQ:CELG) and Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced the initiation of a Phase 2 clinical study of its lead compound ACE-011 in patients with multiple myeloma. ACE-011 is being developed to treat bone loss associated with multiple myeloma and other cancers. The clinical study is designed to assess the safety and efficacy of ACE-011 in multiple...

2008-10-14 09:00:44

The Multiple Myeloma Research Consortium has initiated a three-drug combination study of elotuzumab, a humanized anti-CS1 monoclonal IgG1 antibody administered intravenously, in combination with Revlimid, and dexamethasone for the treatment of multiple myeloma in patients who are experiencing a relapse. Emory University's Winship Cancer Institute, Washington University, and St Vincent's Comprehensive Cancer Center of Saint Vincent Catholic Medical Centers of New York will evaluate the...

2008-10-13 12:00:41

The Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a three-drug combination study of elotuzumab (also known as HuLuc63), a humanized anti-CS1 monoclonal IgG1 antibody administered intravenously, in combination with REVLIMID(R) (lenalidomide), and dexamethasone for the treatment of multiple myeloma in patients who are experiencing a relapse. Emory University's Winship Cancer Institute, Washington University, and St. Vincent's Comprehensive Cancer Center of...

2008-09-29 09:00:57

The International Myeloma Foundation (IMF) - supporting research and providing education, advocacy, and support for myeloma patients, families, researchers, and physicians - today heralded the expansion of treatment options for previously untreated patients with multiple myeloma, giving patients in Canada and Europe access to drugs similar to what is available to patients in the United States. The announcement, made on September 8, 2008 by the European Commission, provides for the...

2008-08-25 12:01:19

The Multiple Myeloma Research Consortium has started a Phase I/II clinical trial with the oral immunomodulatory agent pomalidomide in patients who have received at least two prior therapies including treatments with Revlimid and Velcade for injection. The Phase I study is designed to determine maximum tolerated dose of single-agent pomalidomide while the Phase II randomized study will compare the oral compound's efficacy alone against its combination with dexamethasone. Paul Richardson,...


Word of the Day
ramage
  • Boughs or branches.
  • Warbling of birds in trees.
Related